Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Summary
The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.
Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Sequential Parallel Comparison Design (SPCD) Study to Assess the Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) as an Adjunctive Treatment for Patients With Residual Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
145
Start Date
2015-09-01
Completion Date
2017-07-21
Last Updated
2026-05-13
Healthy Volunteers
No
Conditions
Interventions
AVP-786
Placebo
Locations (17)
Cerritos, California, United States
Garden Grove, California, United States
National City, California, United States
Oakland, California, United States
San Diego, California, United States
Washington D.C., District of Columbia, United States
Orlando, Florida, United States
Atlanta, Georgia, United States
Augusta, Georgia, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
Worcester, Massachusetts, United States
Grand Rapids, Michigan, United States
Marlton, New Jersey, United States
Jamaica, New York, United States
New York, New York, United States
Rochester, New York, United States